UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren's syndrome

Author
Alan N Baer, MD, FACP
Section Editor
Robert Fox, MD, PhD
Deputy Editor
Paul L Romain, MD

INTRODUCTION

Sjögren’s syndrome (SS) is a chronic multisystem inflammatory disorder characterized by diminished lacrimal and salivary gland function. This results in the “sicca complex,” a combination of dry eye and dry mouth. A variety of other disease manifestations may also be present, including additional issues related to exocrine gland dysfunction, such as dryness of the skin, nasal passages, and vagina; extraglandular involvement; and systemic symptoms, such as fever and malaise.

SS occurs in a primary form not associated with other diseases and in a secondary form associated with other autoimmune rheumatic conditions, including rheumatoid arthritis and systemic lupus erythematosus.

The treatment of dry mouth, including topical therapy; the use of systemic cholinergic agents and other systemic therapies; and topical and other therapies for the management of other non-ocular sicca symptoms of SS will be reviewed here. Other issues in SS, including the clinical manifestations, the diagnosis, the treatment of dry eye, and the role of systemic therapy in extraglandular manifestations of SS, are discussed separately. (See "Clinical manifestations of Sjögren's syndrome: Exocrine gland disease" and "Clinical manifestations of Sjögren's syndrome: Extraglandular disease" and "Diagnosis and classification of Sjögren's syndrome" and "Treatment of dry eye in Sjögren's syndrome" and "Treatment of systemic and extraglandular manifestations of Sjögren’s syndrome".)

GENERAL APPROACH

Both local and systemic medical therapies are used in the treatment of the different manifestations of Sjögren’s syndrome (SS) [1-4]. These include:

Preventive therapies and attention to other conditions, medications, and environments that may exacerbate dryness complaints

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Apr 13 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008; 37:273.
  2. Wu AJ. Optimizing dry mouth treatment for individuals with Sjögren's syndrome. Rheum Dis Clin North Am 2008; 34:1001.
  3. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.
  4. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8:399.
  5. Plemons JM, Al-Hashimi I, Marek CL, American Dental Association Council on Scientific Affairs. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2014; 145:867.
  6. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006; 2:252.
  7. Fox PC, Cummins MJ, Cummins JM. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjögren's syndrome. J Altern Complement Med 2002; 8:651.
  8. Furness S, Worthington HV, Bryan G, et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; :CD008934.
  9. da Silva Marques DN, da Mata AD, Patto JM, et al. Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sjögren's syndrome: a randomized controlled trial. J Oral Pathol Med 2011; 40:785.
  10. Rugg-Gunn AJ, Maguire A, Gordon PH, et al. Comparison of erosion of dental enamel by four drinks using an intra-oral applicance. Caries Res 1998; 32:337.
  11. Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol 2005; 5:4.
  12. Kerr AR, Corby PM, Shah SS, et al. Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc 2010; 141:1250.
  13. Aframian DJ, Mizrahi B, Granot I, Domb AJ. Evaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biotène mouthwash for dry mouth relief--a pilot study. Quintessence Int 2010; 41:e36.
  14. Papas AS, Joshi A, MacDonald SL, et al. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993; 59:171.
  15. Newbrun E. Current treatment modalities of oral problems of patients with Sjögren's syndrome: caries prevention. Adv Dent Res 1996; 10:29.
  16. Fox PC, Bowman SJ, Segal B, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc 2008; 139:1592.
  17. Jensen JL, Barkvoll P. Clinical implications of the dry mouth. Oral mucosal diseases. Ann N Y Acad Sci 1998; 842:156.
  18. Ship JA, McCutcheon JA, Spivakovsky S, Kerr AR. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil 2007; 34:724.
  19. Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res 2005; 84:596.
  20. van der Reijden WA, van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum 1996; 39:57.
  21. Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J Otolaryngol 2000; 29:28.
  22. Hardt M, Witkowska HE, Webb S, et al. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal Chem 2005; 77:4947.
  23. Alves MB, Motta AC, Messina WC, Migliari DA. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int 2004; 35:392.
  24. Aagaard A, Godiksen S, Teglers PT, et al. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J Oral Pathol Med 1992; 21:376.
  25. Alpöz E, Güneri P, Onder G, et al. The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study. Clin Oral Investig 2008; 12:165.
  26. Visch LL, Gravenmade EJ, Schaub RM, et al. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 1986; 15:395.
  27. Johansson G, Andersson G, Edwardsson S, et al. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation. Gerodontology 2001; 18:87.
  28. Nagy K, Urban E, Fazekas O, et al. Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J Craniofac Surg 2007; 18:1157.
  29. Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999; 35:132.
  30. Shahdad SA, Taylor C, Barclay SC, et al. A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 2005; 14:319.
  31. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002; 46:748.
  32. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001; 101:249.
  33. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med 2002; 162:1293.
  34. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159:174.
  35. Papas AS, Sherrer YS, Charney M, et al. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol 2004; 10:169.
  36. Wu CH, Hsieh SC, Lee KL, et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc 2006; 105:796.
  37. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.
  38. Leung KC, McMillan AS, Wong MC, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol 2008; 27:429.
  39. Cevimeline (Evoxac) for dry mouth. Med Lett Drugs Ther 2000; 42:70.
  40. Maeda M, Araki M, Fujisawa T, et al. A trial of cevimeline hydrochloride (Evoxac) for patients with Sjogren's syndrome and dry mouth. Nishinihon Journal of Dermatology 2004; 66:48.
  41. Katelaris CH. Pilocarpine for dry mouth and dry eye in Sjögren's syndrome. Curr Allergy Asthma Rep 2005; 5:321.
  42. Nelson JD, Friedlaender M, Yeatts RP, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. Adv Exp Med Biol 1998; 438:979.
  43. Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjögren's syndrome. Clin Rheumatol 2007; 26:1320.
  44. Bryne AC. Muscarinic agonists in the treatment of Sjögren's syndrome. A literature review of pilocarpine and cevimeline. 2008.
  45. Nusair S, Rubinow A. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum 1999; 28:360.
  46. Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome. Br Dent J 2007; 202:E17; discussion 404.
  47. Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology 2005; 74:100.
  48. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004; 138:6.
  49. Hendrickson RG, Morocco AP, Greenberg MI. Pilocarpine toxicity and the treatment of xerostomia. J Emerg Med 2004; 26:429.
  50. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312:249.
  51. Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52:360.
  52. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5 Suppl 1:S31.
  53. Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009; 48:796.
  54. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999; 58:253.
  55. Cankaya H, Alpöz E, Karabulut G, et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:62.
  56. Reksten TR, Brokstad KA, Jonsson R, et al. Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome. Int Immunopharmacol 2011; 11:2125.
  57. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960.
  58. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541.
  59. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15:R172.
  60. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310.
  61. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740.
  62. Ring T, Kallenbach M, Praetorius J, et al. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab. Clin Rheumatol 2006; 25:891.
  63. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284.
  64. Izumi M, Eguchi K, Nakamura H, et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome. Ann Rheum Dis 1998; 57:464.
  65. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med 1999; 38:938.
  66. Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993; 11:149.
  67. Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 2007; 66:107.
  68. Ramos-Casals M, Brito-Zerón P, Sisó A, et al. High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007; 34:754.
  69. Dalavanga YA, Detrick B, Hooks JJ, et al. Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome. Ann Rheum Dis 1987; 46:89.
  70. Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann Rheum Dis 1986; 45:732.
  71. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8:R129.
  72. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270.
  73. Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004; 31:96.
  74. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240.
  75. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001; 44:2371.
  76. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum 2002; 46:3301.
  77. Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“Infliximab in patients with primary Sjögren’s syndrome: a pilot study” and “Infliximab in patients with primary Sjögren’s syndrome: one-year followup”). Arthritis Rheum 2013; 65:814.
  78. Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol 1998; 25:896.
  79. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996; 14:555.
  80. van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis 2007; 66:1026.
  81. Willeke P, Schlüter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther 2007; 9:R115.
  82. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008; 67:1437.
  83. ter Borg EJ, Haanen HC, Haas FJ, et al. Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study. Neth J Med 2002; 60:402.
  84. Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol 2007; 17:464.
  85. Pillemer SR, Leakan RA, Sankar V, et al. Prominent adverse effects of thalidomide in primary Sjögren's syndrome. Arthritis Rheum 2004; 51:505.
  86. Hegarty A, Hodgson T. Management of xerostomia and salivary hypofunction. Prog Palliat Care 2008; 16:21.
  87. Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a review. Int J Clin Pract 2010; 64:404.
  88. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999; 175 Suppl 4:6.
  89. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006; 64:784.
  90. Frost-Larsen K, Isager H, Manthorpe R. Sjörgren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978; 1:1579.
  91. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998; 18:255.
  92. Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999; 19:943.
  93. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49:585.
  94. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1:210.
  95. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1:39.
  96. Unoki H, Moriyama A, Tabaru A, et al. Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996; 31:723.
  97. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10:115.
  98. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32:163.
  99. Steller M, Chou L, Daniels TE. Electrical stimulation of salivary flow in patients with Sjögren's syndrome. J Dent Res 1988; 67:1334.
  100. Strietzel FP, Martín-Granizo R, Fedele S, et al. Electrostimulating device in the management of xerostomia. Oral Dis 2007; 13:206.
  101. Fedele S, Wolff A, Strietzel F, et al. Neuroelectrostimulation in treatment of hyposalivation and xerostomia in Sjögren's syndrome: a salivary pacemaker. J Rheumatol 2008; 35:1489.
  102. Strietzel FP, Lafaurie GI, Mendoza GR, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum 2011; 63:180.
  103. Furness S, Bryan G, McMillan R, et al. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013; :CD009603.
  104. List T, Lundeberg T, Lundström I, et al. The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study. Acta Odontol Scand 1998; 56:95.
  105. Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg 1999; 125:561.
  106. Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000; 6:15.
  107. Jedel E. Acupuncture in xerostomia--a systematic review. J Oral Rehabil 2005; 32:392.
  108. Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.
  109. Hamada T, Nakane T, Kimura T, et al. Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trial. Am J Med Sci 1999; 318:146.
  110. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000; 12:391.
  111. Acevedo AM, Montero M, Rojas-Sanchez F, et al. Clinical evaluation of the ability of CaviStat in a mint confection to inhibit the development of dental caries in children. J Clin Dent 2008; 19:1.
  112. Hay KD, Thomson WM. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:271.
  113. Hay KD, Morton RP. The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia. N Z Dent J 2003; 99:46.
  114. Banting DW, Papas A, Clark DC, et al. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology 2000; 17:67.
  115. Zero DT. Are sugar substitutes also anticariogenic? J Am Dent Assoc 2008; 139 Suppl:9S.
  116. Ly KA, Milgrom P, Rothen M. Xylitol, sweeteners, and dental caries. Pediatr Dent 2006; 28:154.
  117. Ly KA, Riedy CA, Milgrom P, et al. Xylitol gummy bear snacks: a school-based randomized clinical trial. BMC Oral Health 2008; 8:20.
  118. Burt BA. The use of sorbitol- and xylitol-sweetened chewing gum in caries control. J Am Dent Assoc 2006; 137:190.
  119. Söderling E. Controversies around Xylitol. Eur J Dent 2009; 3:81.
  120. Daniels TE, Wu AJ. Xerostomia--clinical evaluation and treatment in general practice. J Calif Dent Assoc 2000; 28:933.
  121. Wu AJ. The oral component of Sjögren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep 2003; 5:304.
  122. Isidor F, Brøndum K, Hansen HJ, et al. Outcome of treatment with implant-retained dental prostheses in patients with Sjögren syndrome. Int J Oral Maxillofac Implants 1999; 14:736.
  123. Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants 2009; 24 Suppl:12.
  124. Wood MR, Vermilyea SG, Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. A review of selected dental literature on evidence-based treatment planning for dental implants: report of the Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. J Prosthet Dent 2004; 92:447.
  125. Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol 1989; 68:324.
  126. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18:571.
  127. Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjögren's syndrome. Curr Rheumatol Rep 2003; 5:297.
  128. Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol 1994; 170:835.
  129. Bell M, Askari A, Bookman A, et al. Sjögren's syndrome: a critical review of clinical management. J Rheumatol 1999; 26:2051.
  130. Henkin RI, Talal N, Larson AL, Mattern CF. Abnormalities of taste and smell in Sjogren's syndrome. Ann Intern Med 1972; 76:375.
  131. Yoshida S, Endo S, Tomita H. A double-blind study of the therapeutic efficacy of zinc gluconate on taste disorder. Auris Nasus Larynx 1991; 18:153.
  132. Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998; 82:1938.
  133. Heyneman CA. Zinc deficiency and taste disorders. Ann Pharmacother 1996; 30:186.